Valuation Syros Pharmaceuticals, Inc. Börse Stuttgart
Stocks
0S90
US87184Q2066
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1140 EUR | -12.31% |
|
+42.50% | -41.84% |
| 25-03-23 | Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index | CI |
| 25-03-18 | Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index | CI |
Company Valuation: Syros Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 187.5 | 293.3 | 497 | 201.9 | 72.61 | 202.6 |
| Change | - | 56.45% | 69.48% | -59.37% | -64.04% | 179.01% |
| Enterprise Value (EV) 1 | 87.81 | 227.8 | 389.3 | 123.7 | -66.12 | 125.1 |
| Change | - | 159.39% | 70.91% | -68.21% | -153.44% | 289.26% |
| P/E | -2.92x | -3.68x | -5.95x | -2.36x | -0.48x | -1.34x |
| PBR | 2.39x | 3.78x | 6.74x | 2.37x | 0.57x | 12.4x |
| PEG | - | 2.22x | 2.2x | 0.1x | 0x | 0.1x |
| Capitalization / Revenue | 91.4x | 148x | 32.9x | 8.6x | 4.88x | 20.4x |
| EV / Revenue | 42.8x | 115x | 25.8x | 5.27x | -4.44x | 12.6x |
| EV / EBITDA | -1.4x | -3.04x | -4.91x | -1.28x | 0.54x | -1.01x |
| EV / EBIT | -1.37x | -2.93x | -4.73x | -1.24x | 0.52x | -0.99x |
| EV / FCF | -3.23x | -3.4x | -21.1x | -2.44x | 1x | -1.88x |
| FCF Yield | -30.9% | -29.4% | -4.74% | -41% | 100% | -53.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -19.07 | -18.76 | -18.25 | -13.84 | -7.493 | -5.81 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 2.05 | 1.982 | 15.09 | 23.49 | 14.88 | 9.936 |
| EBITDA 1 | -62.69 | -75.02 | -79.26 | -96.4 | -123.4 | -124.2 |
| EBIT 1 | -64.3 | -77.74 | -82.3 | -99.42 | -126.4 | -126.5 |
| Net income 1 | -62.28 | -75.44 | -84.04 | -86.56 | -94.65 | -164.6 |
| Net Debt 1 | -99.65 | -65.5 | -107.8 | -78.22 | -138.7 | -77.45 |
| Reference price 2 | 55.700000 | 69.100000 | 108.500000 | 32.600000 | 3.590000 | 7.790000 |
| Nbr of stocks (in thousands) | 3,365 | 4,244 | 4,581 | 6,195 | 20,226 | 26,007 |
| Announcement Date | 3/7/19 | 3/5/20 | 3/4/21 | 3/15/22 | 3/2/23 | 3/27/24 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.27x | 5.94x | 17.68x | 0.96% | 48.7B | |
| -22.15x | 304.02x | -19.9x | -.--% | 42.05B | |
| 29.93x | 2.99x | 12.91x | -.--% | 38.26B | |
| 43.85x | 4.94x | 27.58x | -.--% | 37.5B | |
| 29.67x | 8.57x | 21.53x | 0.39% | 31.44B | |
| 33.27x | 5.44x | 24.74x | -.--% | 16.33B | |
| 23.25x | 2.04x | 8.83x | 1.16% | 13.98B | |
| 53.86x | 3.78x | 14.82x | -.--% | 12.68B | |
| Average | 28.12x | 42.22x | 13.52x | 0.31% | 30.12B | |
| Weighted average by Cap. | 24.75x | 57.31x | 12.22x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SYRS Stock
- 0S90 Stock
- Valuation Syros Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
